Background: Limited information is available on the use of natalizumab (NA) in pediatric multiple sclerosis (ped-MS) patients.
Objective: The purpose of this study was to describe the long-term effects of NA in a large cohort of active ped-MS patients.
Methods: Patients with definite ped-MS were treated with NA if in the previous year they had experienced at least two relapses or a severe relapse with incomplete recovery while on immunomodulating treatment, or at least two relapses and new magnetic resonance imaging (MRI) lesions regardless of any prior treatment.
Results: The study included 55 patients (mean age: 14.4 years, mean number of relapses: 4.4, pre-treatment mean disease duration: 25.5 months). They received a median number of 26 infusions. Three relapses occurred during the follow-up, one female patient continued to deteriorate in cognitive functioning. Mean Expanded Disability Status Scale (EDSS) scores decreased from 2.7 to 1.9 at the last visit (p<0.001). During the follow-up the majority of patients remained free from MRI activity. Transient and mild clinical adverse events occurred in 20 patients. Mild hematological abnormalities occurred in seven patients. Anti-JCV antibodies were detected in 20/51 tested patients.
Conclusions: NA was well tolerated in all patients. A strong suppression of disease activity was observed in the majority of patients during the follow-up.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/1352458512471878 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of disease-modifying therapies in pediatric-onset multiple sclerosis: A systematic review of clinical trials and observational studies.
Mult Scler Relat Disord
January 2025
Department of Nutrition and Drug Research, Faculty of Health Sciences, Institute of Public Health, Jagiellonian University Medical College, Skawińska Street 8, 31-066 Krakow, Poland. Electronic address:
Objective: This study aimed to review the efficacy and safety profile of disease-modifying therapies (DMTs) in patients with relapsing pediatric-onset multiple sclerosis (POMS).
Methods: A systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Published randomized controlled trials (RCTs), nonrandomized studies with a control group, large single-arm studies, and ongoing (unpublished) studies investigating the use of approved and unapproved DMTs in POMS were included.
A comparison of natalizumab's effects on SDMT between pediatric-onset and adult-onset multiple sclerosis patients.
Front Neurol
November 2024
Department of Neurosciences, University of Padua, Padova, Italy.
Article Synopsis
- The study focuses on pediatric-onset multiple sclerosis (POMS) patients, who often face cognitive issues, and examines how natalizumab (NTZ) affects their cognitive function compared to adult-onset multiple sclerosis (AOMS) patients.
- Involving 63 patients, researchers monitored cognitive performance using the Symbol Digit Modalities Test (SDMT) over at least 24 months, noting significant cognitive improvement in both POMS and AOMS, with POMS showing greater gains.
- Results suggest that natalizumab not only helps manage disease activity but also enhances cognitive function in POMS, making it a promising treatment option for younger patients.
Directly Isolated Allogeneic Virus-Specific T Cells in Progressive Multifocal Leukoencephalopathy.
JAMA Neurol
October 2024
Department of Neurology, Hannover Medical School, Hannover, Germany.
Article Synopsis
- Progressive multifocal leukoencephalopathy (PML) is a severe viral infection without any approved antiviral treatments, making effective management crucial.
- A study tested a novel treatment approach using directly isolated allogeneic virus-specific (DIAVIS) T cells in 28 patients with PML, showing substantial clinical improvements in 79% of cases.
- The main findings indicate that DIAVIS T cell therapy can stabilize or improve patients' conditions and lower viral loads, although those older in age had worse outcomes, and some patients still experienced rapid deterioration.
Multiple sclerosis in Somali Americans: Nature or nurture?
Mult Scler Relat Disord
October 2024
Department of Neurology, Mayo Clinic, Rochester, MN, USA; Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN, USA. Electronic address:
Background: Differences in the MS course between White and Black populations is well accepted. The existence of a large Somali immigrant population in Minnesota facilitates a study of MS characteristics in this immigrant native African population. The objective of this study was to compare Somali American (SA), African American (AA), and White American (WA) persons with MS (pwMS) regarding clinical features and disease modifying therapy (DMT) use.
View Article and Find Full Text PDFPediatric-onset Multiple Sclerosis treatment: a multicentre observational study comparing natalizumab with fingolimod.
J Neurol
October 2024
Department of Neuroscience, Reproductive Science and Odontostomatology, Multiple Sclerosis Clinical Care and Research Centre, Federico II University, Naples, Italy.
Background: Pediatric-onset Multiple Sclerosis (POMS) patients show more inflammatory disease compared with adult-onset MS. However, highly effective treatments are limited with only fingolimod being approved in Italy and natalizumab prescribed as off-label treatment.
Objectives: to compare the efficacy of natalizumab versus fingolimod in POMS.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!